{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:02:28Z","timestamp":1785301348681,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis E virus (HEV) is an emerging cause of chronic hepatitis and extrahepatic disease in solid organ transplant recipients. Data on kidney transplant populations, particularly in endemic regions, remain limited. This pilot study aimed to quantify the prevalence of HEV exposure and active infection in kidney transplant recipients and examine associations between HEV markers and allograft function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-centre cross-sectional pilot study, 25 adult kidney transplant recipients (mean age 48.9 \u00b1 14.4 years, median 13.0 years post-transplant) with available HEV serology and\/or RNA testing were included. Clinical data, liver enzymes, estimated glomerular filtration rate (eGFR, mL\/min\/1.73 m\u00b2), and urinary albumin-to-creatinine ratio were obtained from medical records; allograft function was categorised as better versus worsening based on longitudinal clinical and laboratory trends documented in medical records. HEV exposure and active infection were assessed using anti-HEV IgG and IgM antibodies (Euroimmun ELISA; reactive \u2265 1.1, borderline 0.8\u20131.1, negative &amp;lt; 0.8) and HEV RNA in serum and stool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anti-HEV antibodies were present in 19\/25 (76%) patients; HEV RNA was detected in 2\/25 (8%) patients, with concurrent serum and stool positivity confirmed in both cases. eGFR data were available in 15 patients (60%). IgG serostatus was not associated with eGFR differences, but IgM-positive recipients had significantly lower eGFR (median 35.5 vs 57.5 mL\/min\/1.73 m\u00b2; p = 0.018; Cliff\u2019s \u03b4 = 0.74) and higher liver enzyme activity. In an exploratory regression model (n = 15), anti-HEV IgM positivity was associated with approximately 29.8 mL\/min\/1.73 m\u00b2 lower eGFR (R\u00b2 = 0.50), though this estimate is hypothesis-generating given the small sample. Anti-HEV IgM was the strongest individual predictor of worsening graft function (OR\u00a0=\u00a03.00; 95% CI 0.37\u201324.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this endemic setting, kidney transplant recipients showed high HEV seroprevalence and an exploratory association between IgM positivity and impaired allograft function. These hypothesis-generating findings support targeted HEV evaluation\u2014including RNA testing\u2014in kidney transplant recipients with unexplained graft dysfunction or mild transaminase elevation in an endemic South-Eastern European setting. Larger longitudinal studies with kidney biopsies are needed to define the renal impact of HEV and determine whether anti-HEV IgM may serve as a risk-stratification marker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneph.2026.1864349","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:34:40Z","timestamp":1785299680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis E virus infection in kidney transplant recipients: a pilot cross-sectional study of serological markers and allograft function in Northern Serbia"],"prefix":"10.3389","volume":"6","author":[{"given":"Sonja B.","family":"Golubovi\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Nephrology and Clinical Immunology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena D.","family":"Stoj\u010devi\u0107 Maleti\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Center for Laboratory Diagnostics, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lada V.","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Nephrology and Clinical Immunology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tama\u0161 R.","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Scientific Veterinary Institute \u201cNovi Sad\u201d","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta V.","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Nephrology and Clinical Immunology, University Clinical Center of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja S.","family":"Ru\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad","place":["Novi Sad, Serbia"]},{"name":"Clinic for Infectious Diseases, University Clinical Centre of Vojvodina","place":["Novi Sad, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0b013e318245f14c","article-title":"Hepatitis E virus and the kidney in solid-organ transplant patients","volume":"93","author":"Kamar","year":"2012","journal-title":"Transplantation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nmni.2015.12.001","article-title":"Hepatitis E virus is the leading cause of acute viral hepatitis in Lothian, Scotland","volume":"10","author":"Kokki","year":"2016","journal-title":"New Microbes New Infect"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-492363","article-title":"Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Versluis","year":"2013","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801238-3.65709-4","article-title":"Hepatitis E virus in solid organ transplantation","volume":"17","author":"Behrendt","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-2042-2","article-title":"Hepatitis E in liver transplant recipients in the Rh\u00f4ne-Alpes region in France","volume":"33","author":"Buffaz","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2163-4","article-title":"Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft-versus-host disease","volume":"94","author":"Bettinger","year":"2015","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000002097","article-title":"Toward systematic screening for persistent hepatitis E virus infections in transplant patients","volume":"102","author":"Ankcorn","year":"2018","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e29939","DOI":"10.1002\/jmv.29939","article-title":"Incidence and risk factors of de novo hepatitis E virus infection after receiving liver transplantation","volume":"96","author":"He","year":"2024","journal-title":"J Med Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4307-6","article-title":"Chronic hepatitis E after kidney transplantation with an antibody response suggestive of reinfection: a case report","volume":"19","author":"Panning","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3350\/cmh.2019.0082","article-title":"Extrahepatic manifestations of hepatitis E virus: an overview","volume":"26","author":"Fousekis","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2018.23.35.1700616","article-title":"Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016","volume":"23","author":"Niederhauser","year":"2018","journal-title":"Euro Surveill"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000002071","article-title":"Hepatitis E virus infection in kidney transplant patients: a single-center study","volume":"102","author":"Lim","year":"2018","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5604\/16652681.1184202","article-title":"Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation","volume":"15","author":"Unzueta","year":"2016","journal-title":"Ann Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1086\/655899","article-title":"Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France","volume":"202","author":"Legrand-Abravanel","year":"2010","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ajt.2023.11.016","article-title":"Hepatitis E virus infection of transplanted kidneys","volume":"24","author":"Schmitz","year":"2024","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i11.3266","article-title":"Hepatitis E in hemodialysis and kidney transplant patients in south-east Italy","volume":"21","author":"Scotto","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.577339","article-title":"Viral hepatitis E and chronicity: a growing public health concern","volume":"11","author":"Thakur","year":"2020","journal-title":"Front Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/mog.0b013e32835ff238","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid-organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1705331","article-title":"Expanding the spectrum of chronic hepatitis E in kidney transplantation: first report of HEV-3ra infection and review of the literature","volume":"12","author":"Matias","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0168-8278(18)31831-2","article-title":"Hepatitis E virus lifecycle and identification of three forms of the ORF2 capsid protein","volume":"68","author":"Montpellier","year":"2018","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12985-024-02401-2","article-title":"The question of screening organ donors for hepatitis E virus: a case report of transmission by kidney transplantation in France and a review of the literature","volume":"21","author":"Solignac","year":"2024","journal-title":"Virol J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031872","article-title":"Acute and persistent hepatitis E virus genotype 3 and 4 infection: clinical features, pathogenesis, and treatment","volume":"9","author":"Kamar","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12353","article-title":"Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin","volume":"17","author":"Del Bello","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12879-026-12567-5","article-title":"Molecular and serodetection of hepatitis E virus among organ donors in the Czech Republic","volume":"26","author":"Slep\u010danov\u00e1","year":"2026","journal-title":"BMC Infect Dis"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1864349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:34:58Z","timestamp":1785299698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1864349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":25,"alternative-id":["10.3389\/fneph.2026.1864349"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1864349","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1864349"}}